Klinik Schillerhöhe
- Address
- Auerbachstr. 110, 70376 Stuttgart, Germany
Klinik Schillerhöhe - Advanced Lung Cancer Research Center
Klinik Schillerhöhe is a specialized center dedicated to advancing precision oncology in thoracic malignancies, with particular expertise in ALK-positive non-small cell lung cancer (ALK+ NSCLC). The center focuses on cutting-edge research involving targeted therapies and molecular characterization of lung cancer patients, contributing to the optimization of treatment strategies for patients with locally advanced or metastatic disease.
- Second-generation tyrosine kinase inhibitor (TKI) therapy in ALK+ NSCLC
- Deep phenotyping and molecular profiling of lung cancer patients
- First-line treatment strategies with targeted agents including brigatinib
The research team employs sophisticated assessment methodologies including RECIST v1.1 criteria to evaluate treatment efficacy and progression-free survival outcomes. Through comparative effectiveness studies of novel anaplastic lymphoma kinase (ALK) inhibitors, the center strives to identify optimal therapeutic approaches that can improve clinical outcomes for patients with advanced lung cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinik Schillerhöhe
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy Comparison of Brigatinib Versus Second-Generation TKIs in First-Line Treatment of Locally Advanced or Metastatic ALK-Positive NSCLC | Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH | Phase II | Not Recruiting | Mar 2020 | May 2026 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alectinib | 1 | Unknown | 2020-03-30 | 2020-03-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.